Heart failure

The Lancet

Volumn 390, Issue 10106, 2017, Pages 1981-1995

  Metra, Marco ^a   Teerlink, John R ^b,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARDIAC MYOSIN ACTIVATOR; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; MINERALOCORTICOID ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; AGING; CARDIOVASCULAR MAGNETIC RESONANCE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SAFETY; AGED; CAUSE OF DEATH; DISEASE EXACERBATION; FEMALE; GLOBAL HEALTH; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAUSE OF DEATH; COMORBIDITY; DISEASE PROGRESSION; FEMALE; GLOBAL HEALTH; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 85018306708     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31071-1     Document Type: Review

References (143)

1. Ponikowski, P, Voors, AA, Anker, SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
2. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), 1810–1852.
3. van Riet, EE, Hoes, AW, Wagenaar, KP, Limburg, A, Landman, MA, Rutten, FH, Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18 (2016), 242–252.
4. Bui, AL, Horwich, TB, Fonarow, GC, Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8 (2011), 30–41.
5. Owan, TE, Hodge, DO, Herges, RM, Jacobsen, SJ, Roger, VL, Redfield, MM, Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
6. Gerber, Y, Weston, SA, Redfield, MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 175 (2015), 996–1004.
7. Stevenson, LW, Heart failure with better ejection fraction: a modern diagnosis. Circulation 129 (2014), 2364–2367.
8. Basuray, A, French, B, Ky, B, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 129 (2014), 2380–2387.
9. Mosterd, A, Hoes, AW, de Bruyne, MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J 20 (1999), 447–455.
10. Redfield, MM, Jacobsen, SJ, Burnett, JC Jr, Mahoney, DW, Bailey, KR, Rodeheffer, RJ, Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003), 194–202.
11. Bleumink, GS, Knetsch, AM, Sturkenboom, MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 25 (2004), 1614–1619.
12. Mozaffarian, D, Benjamin, EJ, Go, AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–360.
13. Lloyd-Jones, DM, Larson, MG, Leip, EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 (2002), 3068–3072.
14. Heidenreich, PA, Albert, NM, Allen, LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
15. Jhund, PS, Macintyre, K, Simpson, CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5·1 million people. Circulation 119 (2009), 515–523.
16. Bueno, H, Ross, JS, Wang, Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA 303 (2010), 2141–2147.
17. Crespo-Leiro, MG, Anker, SD, Maggioni, AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18 (2016), 613–625.
18. Braunwald, E, Heart failure. JACC Heart Fail 1 (2013), 1–20.
19. Shah, AM, Mann, DL, In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 378 (2011), 704–712.
20. Damman, K, Valente, MA, Voors, AA, O'Connor, CM, van Veldhuisen, DJ, Hillege, HL, Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35 (2014), 455–469.
21. Damman, K, Testani, JM, The kidney in heart failure: an update. Eur Heart J 36 (2015), 1437–1444.
22. Valentova, M, von Haehling, S, Bauditz, J, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J 37 (2016), 1684–1691.
23. McMurray, JJ, Packer, M, Desai, AS, et al., for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
24. McMurray, JJ, Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail 17 (2015), 242–247.
25. Kraigher-Krainer, E, Shah, AM, Gupta, DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 63 (2014), 447–456.
26. Shah, AM, Claggett, B, Sweitzer, NK, et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132 (2015), 402–414.
27. Paulus, WJ, Tschope, C, A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
28. Ter Maaten, JM, Damman, K, Verhaar, MC, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18 (2016), 588–598.
29. Franssen, C, Chen, S, Unger, A, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 4 (2016), 312–324.
30. Kelkar, AA, Spertus, J, Pang, P, et al. Utility of patient-reported outcome instruments in heart failure. JACC Heart Fail 4 (2016), 165–175.
31. McMurray, JJ, Adamopoulos, S, Anker, SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
32. de Boer, RA, Daniels, LB, Maisel, AS, Januzzi, JL Jr, State of the art: newer biomarkers in heart failure. Eur J Heart Fail 17 (2015), 559–569.
33. Pocock, SJ, Ariti, CA, McMurray, JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 34 (2013), 1404–1413.
34. Cikes, M, Solomon, SD, Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J 37 (2016), 1642–1650.
35. Nagueh, SF, Appleton, CP, Gillebert, TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10 (2009), 165–193.
36. Flachskampf, FA, Biering-Sorensen, T, Solomon, SD, Duvernoy, O, Bjerner, T, Smiseth, OA, Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging 8 (2015), 1071–1093.
37. Erdei, T, Smiseth, OA, Marino, P, Fraser, AG, A systematic review of diastolic stress tests in heart failure with preserved ejection fraction, with proposals from the EU-FP7 MEDIA study group. Eur J Heart Fail 16 (2014), 1345–1361.
38. Cooper, LT, Baughman, KL, Feldman, AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur Heart J 28 (2007), 3076–3093.
39. Corra, U, Piepoli, MF, Adamopoulos, S, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the ESC. Eur J Heart Fail 16 (2014), 929–941.
40. Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
41. Wright, JT Jr, Williamson, JD, Whelton, PK, et al., for the SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 (2015), 2103–2116.
42. Ledwidge, M, Gallagher, J, Conlon, C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310 (2013), 66–74.
43. Marso, SP, Daniels, GH, Brown-Frandsen, K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
44. Margulies, KB, Hernandez, AF, Redfield, MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
45. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
46. Fitchett, D, Zinman, B, Wanner, C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37 (2016), 1526–1534.
47. Balion, C, McKelvie, R, Don-Wauchope, AC, et al. B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev 19 (2014), 553–564.
48. Troughton, RW, Frampton, CM, Brunner-La Rocca, HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 35 (2014), 1559–1567.
49. Kuck, KH, Bordachar, P, Borggrefe, M, et al. New devices in heart failure: a European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. Europace 16 (2014), 109–128.
50. Abraham, WT, Adamson, PB, Bourge, RC, et al., for the CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377 (2011), 658–666.
51. Abraham, WT, Stevenson, LW, Bourge, RC, Lindenfeld, JA, Bauman, JG, Adamson, PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387 (2016), 453–461.
52. van Veldhuisen, DJ, Braunschweig, F, Conraads, V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 124 (2011), 1719–1726.
53. Yancy, CW, Jessup, M, Bozkurt, B, et al., for the Writing Committee Members. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 (2016), e282–e293.
54. Swedberg, K, Komajda, M, Bohm, M, et al., for the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
55. Psotka, MA, Teerlink, JR, Ivabradine: role in the chronic heart failure armamentarium. Circulation 133 (2016), 2066–2075.
56. Cannon, JA, Shen, L, Jhund, PS, et al., for the PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19 (2017), 129–137.
57. Metra, M, Ponikowski, P, Dickstein, K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9 (2007), 684–694.
58. Stevenson, LW, Pagani, FD, Young, JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 28 (2009), 535–541.
59. Teuteberg, JJ, Stewart, GC, Jessup, M, et al. Implant strategies change over time and impact outcomes: insights from the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). JACC Heart Fail 1 (2013), 369–378.
60. Jorde, UP, Kushwaha, SS, Tatooles, AJ, et al. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
61. Estep, JD, Starling, RC, Horstmanshof, DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 66 (2015), 1747–1761.
62. Smedira, NG, Hoercher, KJ, Lima, B, et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail 1 (2013), 31–39.
63. Miller, LW, Guglin, M, Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol 61 (2013), 1209–1221.
64. Mancini, D, Colombo, PC, Left ventricular assist devices: a rapidly evolving alternative to transplant. J Am Coll Cardiol 65 (2015), 2542–2555.
65. Gheorghiade, M, Greene, SJ, Butler, J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314 (2015), 2251–2262.
66. Pieske, B, Maggioni, AP, Lam, CS, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J, 2017, 10.1093/eurheartj/ehw593 published online Mar 22.
67. Hasenfuss, G, Teerlink, JR, Cardiac inotropes: current agents and future directions. Eur Heart J 32 (2011), 1838–1845.
68. Liu, LC, Dorhout, B, van der Meer, P, Teerlink, JR, Voors, AA, Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs 25 (2016), 117–127.
69. Teerlink, JR, Felker, GM, McMurray, JJ, et al., for the COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388 (2016), 2895–2903.
70. Greenberg, B, Butler, J, Felker, GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387 (2016), 1178–1186.
71. Braunwald, E, The war against heart failure: the Lancet lecture. Lancet 385 (2015), 812–824.
72. Schussler-Lenz, M, Beuneu, C, Menezes-Ferreira, M, et al. Cell-based therapies for cardiac repair: a meeting report on scientific observations and European regulatory viewpoints. Eur J Heart Fail 18 (2016), 133–141.
73. Desai, AS, Swedberg, K, McMurray, JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 50 (2007), 1959–1966.
74. Konstam, MA, Hyperkalaemia in heart failure: binding the patient to improved treatment?. Eur J Heart Fail 17 (2015), 997–999.
75. Bramlage, P, Swift, SL, Thoenes, M, Minguet, J, Ferrero, C, Schmieder, RE, Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail 18 (2016), 28–37.
76. Xiong, Q, Lau, YC, Senoo, K, Lane, DA, Hong, K, Lip, GY, Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 17 (2015), 1192–1200.
77. Zannad, F, Greenberg, B, Cleland, JG, et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 17 (2015), 735–742.
78. Homma, S, Thompson, JL, Pullicino, PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366 (2012), 1859–1869.
79. Hasenfuß, G, Hayward, C, Burkhoff, D, et al., for the REDUCE LAP-HF study investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 387 (2016), 1298–1304.
80. Del Trigo, M, Bergeron, S, Bernier, M, et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet 387 (2016), 1290–1297.
81. Iung, B, Vahanian, A, Valvular disease: implications of the new AHA/ACC valvular disease guidelines. Nat Rev Cardiol 11 (2014), 317–318.
82. Mann, DL, Lee, RJ, Coats, AJ, et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail 18 (2016), 314–325.
83. Pitt, B, Pfeffer, MA, Assmann, SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
84. Pfeffer, MA, Claggett, B, Assmann, SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
85. Shah, SJ, Katz, DH, Selvaraj, S, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131 (2015), 269–279.
86. Senni, M, Paulus, WJ, Gavazzi, A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35 (2014), 2797–2815.
87. Shah, SJ, Kitzman, DW, Borlaug, BA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134 (2016), 73–90.
88. ClinicalTrials.gov. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). https://clinicaltrials.gov/ct2/show/NCT01920711?term=LCZ696&rank=29 (accessed Sept 15, 2016).
89. Borlaug, BA, Koepp, KE, Melenovsky, V, Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 66 (2015), 1672–1682.
90. Redfield, MM, Anstrom, KJ, Levine, JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373 (2015), 2314–2324.
91. van Deursen, VM, Urso, R, Laroche, C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 16 (2014), 103–111.
92. Ter Maaten, JM, Damman, K, Verhaar, MC, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 18 (2016), 588–598.
93. Velazquez, EJ, Lee, KL, Jones, RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 374 (2016), 1511–1520.
94. Anker, SD, Comin Colet, J, Filippatos, G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
95. Lip, GY, Heinzel, FR, Gaita, F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail 17 (2015), 848–874.
96. Van Gelder, IC, Rienstra, M, Crijns, HJ, Olshansky, B, Rate control in atrial fibrillation. Lancet 388 (2016), 818–828.
97. Piccini, JP, Fauchier, L, Rhythm control in atrial fibrillation. Lancet 388 (2016), 829–840.
98. Authors/Task Force Members, Ryden, L, Grant, PJ, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
99. Swedberg, K, Young, JB, Anand, IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 (2013), 1210–1219.
100. Bello, NA, Lewis, EF, Desai, AS, et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail, 17, 2015, 6.
101. Jankowska, EA, Malyszko, J, Ardehali, H, et al. Iron status in patients with chronic heart failure. Eur Heart J 34 (2013), 827–834.
102. Ponikowski, P, van Veldhuisen, DJ, Comin-Colet, J, et al., for the CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 (2015), 657–668.
103. Jankowska, EA, Tkaczyszyn, M, Suchocki, T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail 18 (2016), 786–795.
104. Metra, M, Cotter, G, Davison, BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61 (2013), 196–206.
105. Rusinaru, D, Tribouilloy, C, Berry, C, et al., for the MAGGIC Investigators. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis: meta-analysis global group in chronic heart failure (MAGGIC). Eur J Heart Fail 14 (2012), 1139–1146.
106. Grodin, JL, Simon, J, Hachamovitch, R, et al. Prognostic role of serum chloride levels in acute decompensated heart failure. J Am Coll Cardiol 66 (2015), 659–666.
107. Nikolaou, M, Parissis, J, Yilmaz, MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J 34 (2013), 742–749.
108. Cowie, MR, Woehrle, H, Wegscheider, K, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 373 (2015), 1095–1105.
109. Maisel, A, Neath, SX, Landsberg, J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (biomarkers in acute heart failure) trial. Eur J Heart Fail 14 (2012), 278–286.
110. Lazzarini, V, Mentz, RJ, Fiuzat, M, Metra, M, O'Connor, CM, Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail 15 (2013), 717–723.
111. Felker, GM, Teerlink, JR, Diagnosis and management of acute heart failure. Mann, DL, Zipes, DP, Libby, P, Bonow, RO, (eds.) Braunwald's heart disease: a textbook of cardiovascular medicine, 10th edn., 2015, Elsevier Saunders, Philadelphia, PA, 484–509.
112. Solomon, SD, Dobson, J, Pocock, S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007), 1482–1487.
113. Kristensen, SL, Jhund, PS, Kober, L, et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail 17 (2015), 169–176.
114. Teerlink, JR, Felker, GM, McMurray, JJ, et al., for the ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF Study. J Am Coll Cardiol 67 (2016), 1444–1455.
115. Gheorghiade, M, Follath, F, Ponikowski, P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12 (2010), 423–433.
116. Hanberg, JS, Sury, K, Wilson, FP, et al. Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol 67 (2016), 2199–2208.
117. Mullens, W, Abrahams, Z, Francis, GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 (2009), 589–596.
118. Salah, K, Kok, WE, Eurlings, LW, et al. Competing risk of cardiac status and renal function during hospitalization for acute decompensated heart failure. JACC Heart Fail 3 (2015), 751–761.
119. Valente, MA, Voors, AA, Damman, K, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35 (2014), 1284–1293.
120. Butler, J, Gheorghiade, M, Kelkar, A, et al. In-hospital worsening heart failure. Eur J Heart Fail 17 (2015), 1104–1113.
121. Collins, SP, Storrow, AB, Albert, NM, et al. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. J Card Fail 21 (2015), 27–43.
122. Mebazaa, A, Yilmaz, MB, Levy, P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17 (2015), 544–558.
123. Chouihed, T, Coiro, S, Zannad, F, Girerd, N, Lung ultrasound: a diagnostic and prognostic tool at every step in the pathway of care for acute heart failure. Am J Emerg Med 34 (2016), 656–657.
124. Picano, E, Pellikka, PA, Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J 37 (2016), 2097–2104.
125. Metra, M, Cleland, JG, Weatherley, BD, et al. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. Eur J Heart Fail 12 (2010), 499–507.
126. Bottle, A, Goudie, R, Cowie, MR, Bell, D, Aylin, P, Relation between process measures and diagnosis-specific readmission rates in patients with heart failure. Heart 101 (2015), 1704–1710.
127. Felker, GM, Lee, KL, Bull, DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
128. Bart, BA, Goldsmith, SR, Lee, KL, et al. Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. J Card Fail 18 (2012), 176–182.
129. Costanzo, MR, Negoianu, D, Jaski, BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail 4 (2016), 95–105.
130. Singh, A, Laribi, S, Teerlink, JR, Mebazaa, A, Agents with vasodilator properties in acute heart failure. Eur Heart J, 2016, 10.1093/eurheartj/ehv755 published online Feb 4.
131. Wakai, A, McCabe, A, Kidney, R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev, 8, 2013 CD005151.
132. Dworzynski, K, Roberts, E, Ludman, A, Mant, J, Guideline Development Group of the National Institute for Health and Care Excellence. Diagnosing and managing acute heart failure in adults: summary of NICE guidance. BMJ, 349, 2014, g5695.
133. Teerlink, JR, Metra, M, Zaca, V, et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 14 (2009), 243–253.
134. De Backer, D, Biston, P, Devriendt, J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 (2010), 779–789.
135. Prins, KW, Neill, JM, Tyler, JO, Eckman, PM, Duval, S, Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail 3 (2015), 647–653.
136. Peacock, WF, Hollander, JE, Diercks, DB, Lopatin, M, Fonarow, G, Emerman, CL, Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 25 (2008), 205–209.
137. Bikdeli, B, Strait, KM, Dharmarajan, K, et al. Intravenous fluids in acute decompensated heart failure. JACC Heart Fail 3 (2015), 127–133.
138. Teerlink, JR, Metra, M, Felker, GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373 (2009), 1429–1439.
139. Teerlink, JR, Cotter, G, Davison, BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
140. Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail (in press).
141. Anker, SD, Ponikowski, P, Mitrovic, V, Peacock, WF, Filippatos, G, Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J 36 (2015), 715–723.
142. Felker, GM, Butler, J, Collins, SP, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure). JACC Heart Fail 3 (2015), 193–201.
143. Asakura, M, Yamamoto, H, Asai, K, et al. Rationale and design of the double-blind, randomized, placebo-controlled multicenter trial on efficacy of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER). Cardiovasc Drugs Ther 29 (2015), 179–185.